Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective
This study highlights the burden that chronic diseases impose on healthcare systems and society, emphasising the relevance of incorporating a societal perspective in cost-effectiveness analyses. The analysis estimates that adding finerenone to SoC treatment for patients with mild to advanced CKD associated with is cost-effective from a healthcare and societal perspective.
Authors
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Michał Pochopień
- Stephan J. L. Bakker (ORCID: https://orcid.org/0000-0003-3356-6791)
- Sara W. Quist (ORCID: https://orcid.org/0000-0003-3871-4239)
- Jeroen Paulissen (ORCID: https://orcid.org/0000-0003-2742-9870)
- J. Van Loon
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- University of Namibia (NA)
- Dialyse Centrum Groningen (NL)
- Bohn Stafleu van Loghum (Netherlands) (NL)
Publication Details
- Journal
- BMJ Public Health
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/bmjph-2024-001288
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.13
Funders
- Pharmaceuticals Bayer